There is inadequate substance use disorder support for people who are incarcerated or are leaving incarceration. But there are opportunities to make improvements, experts say.
Affect Therapeutics' $16 million Series A funding round was led by ARTIS Ventures and included participation from AlleyCorp, CityLight, LifeArc Ventures, Samsung Next and What If Ventures. In total, Affect Therapeutics has raised about $26 million, said Kristin Muhlner, co-founder and CEO of the company.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
More than 580,000 individuals are experiencing homelessness in the U.S., and hospitals across the country have dedicated programs to caring for this incredibly at-risk population. The indicatives at UCLA Health, Boston Health Care for the Homeless Program and University of Illinois Health focus on street medicine, connecting patients to housing and integrating behavioral and preventive care into primary care.
The United States’ response to addiction and substance use disorders is a criminal justice response and not a public health response — but it shouldn’t be that way, one expert said at Engage at HLTH.
As the Covid-19 crisis puts pressure on outpatient providers to facilitate remote care, some addiction professionals have set aside their skepticism and opened digital care channels.
AxialHealthcare, a startup building software to manage opioid prescriptions and addiction, raised $15 million in funding. The company plans to use the new funds to build out tools to help addicted patients find help.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Cerevel will take on several clinical and preclinical candidates from Pfizer, which divested from neuroscience this year and will take a 25 percent stake in the new company.
The Michigan team is pushing its new prescribing guidelines online, in hopes of encouraging other hospitals to adopt similar practices.
Dreamit Health's ninth cohort includes startups using big data analytics for clinical decision support to address opioid addiction and virtual reality to ease chronic pain. There's also a new managing director for the program.
The FDA's clearance for the prescribed app, aimed at individuals as part of outpatient therapy for substance use disorders spanning alcohol, cocaine, marijuana, and stimulants, is a major milestone for digital therapeutics and suggests more companies will seek FDA approval.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
The idea is that if clinicians have a better understanding of their patients' entire medical histories including their "addiction treatment" histories, they will avoid prescribing opioids to patients in recovery.
At this year's American Telemedicine Association conference, Patrick J. Kennedy shared his personal journey with mental health and outlined how telemedicine can play a vital role in mental health treatment and awareness.
In February of this year, the FDA approved the Narcan nasal spray to revive patients that had overdosed on opioid drugs. But the real story of 2016 was how widely that antidote was needed. The epidemic reached all corners of America in deadly new synthetic forms, raising unprecedented awareness about the dangers of opioid use -- without yet bringing the death toll down.
"We are patients as designers, reinventing a system we have intimate experience with from the ground up," said Workit Health Co-founder Robin McIntosh.
"The highest utilizers of the Medicaid system, if you take out long-term care and people going into nursing homes, it’s people who have mental health issues and addiction."